An oral multikinase inhibitor has been approved by the FDA for treatment of metastatic colorectal cancer as well as advanced gastrointestinal stromal tumors (GIST). Regorafenib is marketed by Bayer HealthCare Pharmaceuticals as Stivarga.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content